Abstract
Chimeric Antigen Receptor (CAR) T-cell therapy, being one of the most critical treatment regimens for certain types of lymphomas, leukemias, and multiple myeloma, is experiencing ever-increasing demand. Its high expense and low availability have inflicted many issues among patients in need of this treatment. This paper aims to address these socioeconomic problems by concentrating on the future and current development of transposon-based CAR-T cell production in immunotherapy. Switching viral vectors to transposon-based vectors will greatly decrease the cost and manufacturing time of this personalized product. Transposon vectors also have advantages over viral vectors in sense of DNA carrying capacity and safety matters. Research organizations such as the CARAMBA Project are undertaking new transposon technology in the hope to increase the accessibility of CAR-T cell immunotherapies. Transposon-based CAR-T cell production may pave way for therapeutically and financially satisfying immunotherapies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
